Valuing pharma companies isn’t the same as valuing non-pharma companies, for several reasons. Traditional business considerations are compounded by patent law and FDA approval processes when evaluating the investment potential of…
The post Valuation of…
Valuation of Pharma Companies: 5 Key Considerations Read Post »
Amid public outcry over rising costs of brand-name drugs, the prices of generic medicines have been falling, raising fears about the sustainability and profitability of major generics companies. But some…
The post Opportunities for Generic Drug Develop…
This paper was originally published by Melek Simsek, Berrie Meijer, Adriaan A.van Bodegraven, Nanne K.H. de Boer, and Chris J.J. Mulder in Drug Discovery Today Volume 23, Issue 1, January…
The post Finding hidden treasures in old drugs: the challenges …
When referring to “big data” in the context of the drug industry, one should essentially think of a collection of datasets with the help of which companies are able to…
The post How Big Data Is Remodelling The Drug Industry appeared first on DrugPatent…
New book based on 20 years providing business guidance to drug companies [Free Sample] [Buy printed book from Amazon] [More Details] Make
Generic drugs perform better financially if they get to market first. The advantage is amplified if they get there more than one month ahead of competitors.
The post First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Ent…
Loss of exclusivity doesn’t mean the end of the income stream for branded drugs. Here’s how drug companies can mitigate the effects of drug patent expiration.
The post 6 Ways to Maximize Product Value as Loss of Exclusivity Approaches appeared first on…
6 Ways to Maximize Product Value as Loss of Exclusivity Approaches Read Post »
Considering switching to DrugPatentWatch? See why others have come to us. Switch to DrugPatentWatch
The post DrugPatentWatch Alternatives appeared first on DrugPatentWatch – Make Better Decisions.
This paper was originally published by Ingrid Freije, Stéphane Lamouche, and Mario Tanguay in Therapeutic Innovation & Regulatory Science under a Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/…
Generic drug makers must tailor European market entry strategies to each country. Moreover, they must address the sequence in which they want to enter markets.
The post Generic Drug Market Entry in Europe: Why a Tailored Approach Is Best appeared first…
Generic Drug Market Entry in Europe: Why a Tailored Approach Is Best Read Post »
Get new actionable insights and updates from BiotechBlog
